Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. (Q48609141)
Jump to navigation
Jump to search
scientific article published in August 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. |
scientific article published in August 2014 |
Statements
1 reference
Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. (English)
1 reference
1 reference
1 reference
Hugo A Katus
1 reference
Arnt V Kristen
1 reference
Ute Hegenbart
1 reference
Philipp A Schnabel
1 reference
Evangelos Giannitsis
1 reference
Moritz Biener
1 reference
Stefan Hardt
1 reference
1 August 2014
1 reference
176
1 reference
1113-1115
1 reference
3
1 reference
Identifiers
1 reference
1 reference